TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06000956: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Protocol of the Efficacy and Safety of Jitongning Tablets for Treating Spondyloarthritis (Kidney Yang Deficiency and Blood Stasis Obstr

Sponsor: Tasly Pharmaceutical Group Co., Ltd · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT06000956 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06000956 Rescue Dossier →